{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:42:30Z","timestamp":1786207350812,"version":"build-2736575974"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1245\/s10434-026-20076-7","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:44:38Z","timestamp":1782513878000},"page":"8561-8562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ASO Author Reflections: Biological Limitations of ctDNA Surveillance in Colon Cancer: The Peritoneal Conundrum"],"prefix":"10.1245","volume":"33","author":[{"given":"Kwasi Ansere","family":"Ofori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Turaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"346","key":"20076_CR1","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/SCITRANSLMED.AAF6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92. https:\/\/doi.org\/10.1126\/SCITRANSLMED.AAF6219.","journal-title":"Sci Transl Med."},{"issue":"12","key":"20076_CR2","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/JAMAONCOL.2019.3616","volume":"5","author":"J Tie","year":"2019","unstructured":"Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019;5(12):1710\u20137. https:\/\/doi.org\/10.1001\/JAMAONCOL.2019.3616.","journal-title":"JAMA Oncol."},{"issue":"12","key":"20076_CR3","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie J, Wang Y, Loree JM, et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat Med. 2025;31(12):4291\u2013300. https:\/\/doi.org\/10.1038\/s41591-025-04030-w.","journal-title":"Nat Med."},{"key":"20076_CR4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-026-19903-8","author":"KA Ofori","year":"2026","unstructured":"Ofori KA, Smart H, Liu S, et al. Peritoneal metastases in stage II-III colon cancer represent a blind spot for circulating tumor DNA surveillance. Ann Surg Oncol. 2026. https:\/\/doi.org\/10.1245\/s10434-026-19903-8.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20076-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20076-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20076-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:48:15Z","timestamp":1786204095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20076-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":4,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["20076"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20076-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kiran Turaga has served on an AstraZeneca advisory board.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}